Castle Biosciences, Inc. (CSTL)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous Close | 35.44 |
| Open | 35.31 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 34.11 - 36.49 |
| 52 Week Range | 31.46 - 107.69 |
| Volume | |
| Avg. Volume | 245,560 |
| Market Cap | 884.752M |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | Mar. 07, 2022 - Mar. 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.29 |
- Business Wire
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
FRIENDSWOOD, Texas, January 24, 2022--Castle Biosciences will present data highlighting its portfolio of skin cancer tests at Maui Derm for Dermatologists 2022, Jan. 24-28, 2022.
- Business Wire
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
FRIENDSWOOD, Texas, January 13, 2022--Castle announced the publication of clinical performance study data related to DecisionDx®-SCC in Future Oncology.
- Business Wire
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
FRIENDSWOOD, Texas, January 12, 2022--Castle announced the publication of a study in Ocular Oncology and Pathology related to the Company's DecisionDx®-UMSeq 7-gene DNA sequencing panel.
